Merus BV

MRUS

----

Current ValuationThe current P/E ratio is -17.91, within the reasonable range, cheaper than 79.66% of the time in the past 5 years, and the industry ranks 515/602, the industry Median -2.08.

-17.91xP/E

Stock price--

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GILDUSGilead Sciences	-55.20x	148.77%	$178.84B
MRNAUSModerna	-23.75x	15.53%	$74.84B
CSLLYUSCSL Limited	-23.15x	--	$59.71B
NTRAUSNatera	-300.25x	6.91%	$57.75B
RVMDUSRevolution Medicines	-24.23x	62.27%	$42.84B
ROIVUSRoivant Sciences	-96.39x	146.49%	$25.66B
BNTXUSBioNTech SE	-12.28x	15.84%	$24.05B
INSMUSInsmed	-26.25x	74.61%	$22.98B
SMMTUSSummit Therapeutics	-16.13x	19.55%	$13.81B
BBIOUSBridgebio Pharma	-18.92x	28.48%	$13.09B
MDGLUSMadrigal Pharma	-35.28x	51.06%	$11.47B
TWSTUSTwist Bioscience	-80.40x	20.00%	$10.99B
IBRXUSImmunityBio	-10.35x	151.32%	$10.27B
PCVXUSVaxcyte	-9.33x	54.35%	$9.93B
KYMRUSKymera Therapeutics	-29.41x	4.94%	$8.81B
ARWRUSArrowHead Pharma	-27.17x	36,308.30%	$8.69B
CYTKUSCytokinetics	-9.54x	6.37%	$8.53B
PRAXUSPraxis Precision Medicines	-23.06x	3.05%	$7.82B
ABVXUSAbivax SA	-16.51x	22.49%	$7.69B
IONSUSIonis Pharma	-12.94x	50.60%	$7.31B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.